Photo credit Source : www.aumanufacturing.com.au
Cyclopharm Secures Agreement to Supply Veterans Health Administration with Technegas Imaging System Components
Cyclopharm Secures Agreement to Supply Veterans Health Administration with Technegas Imaging System
Radiopharmaceutical system manufacturer Cyclopharm has made a significant breakthrough by entering into an agreement to supply the Veterans Health Administration (VA) with the pharmaceutical and consumable components of its Technegas imaging system. This marks a major milestone for the company as the VA is the largest US government health care system.
The Interim Agreement immediately grants access to the Technegas imaging system to the 120 Veterans Affairs hospitals that have nuclear medicine departments. This agreement is the first step towards Technegas being included on the broader US Federal Supply Schedule (FSS), which is a simplified procurement service for US federal agencies including the Department of Defense (DoD), Veterans Administration (VA), and Public Health Service (PHS) hospitals.
Cyclopharm CEO James McBrayer expressed the importance of securing this Interim Agreement, stating that it streamlines the United States federal government procurement process. By bypassing the need for separate contracts with each of the 20 Regional Procurement Offices within the VA, Cyclopharm can expedite the deployment of Technegas and maintain closer relationships with its customers.
Technegas, which was approved for sale in the US by the US Food and Drug Administration in October 2023, is an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging. McBrayer highlighted the success of Technegas in other countries and the expanding indications for its use in respiratory medicine.
In addition to the pharmaceutical component agreement, Cyclopharm is also working on the necessary registrations to include the Technegas System, the medical device component of Technegas, in the streamlined procurement process. The company has also received its first purchase order for Technegas from a Department of Defense (DoD) hospital.
This agreement with the VA and the progress in the US market demonstrate the growing traction and success of Technegas globally. Cyclopharm’s innovative imaging system is poised to make a significant impact in the nuclear medicine market, benefiting both patients and healthcare providers alike.
